A Randomized, Double-Blind, Placebo-Controlled Study of N-3 Fatty Acid on Plasma Triglyceride Levels in Hypertriglyceridemic HIV Patients Receiving Highly Active Antiretroviral Therapy

TRIAL ALERTS

View Clinical Trial (Medical Research Study)

City:		Washington
State:		District of Columbia
Zip Code:		20007

Conditions:		HIV Infections - AIDS - Dyslipidemia - Hypertriglyceridemia
Purpose:		The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia. In addition, we, the researchers, will evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and inflammation.
Study Summary:		Hypertriglyceridemia is common among HIV-infected patients receiving Highly Active Antiretroviral Therapy (HAART). Although fibrates, statins, and niacin have all been used in the management of hypertriglyceridemia in HIV-infected patients, optimal control is difficult to achieve and other agents are needed. Omega-3 fatty acids are effective for lowering triglycerides in patients without HIV infection, but experience in HIV-infected patients is limited. In addition, omega-3 fatty acids may also have secondary benefits in decreasing bone resorption and decreasing markers of systemic inflammation. The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia. In addition, we will evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and inflammation. It is 8- week randomized, double-blind trial of omega-3 fatty acids (LOVAZA, GSK, Inc) compared to placebo in 48 HAART-treated HIV-infected patients with triglycerides between 250 and 1000 mg/dl receiving dietary counseling. Subjects will be recruited from three centers (Johns Hopkins, Georgetown, and Los Angeles VAMC). The primary endpoint will be the change in triglyceride concentrations from baseline in the LOVAZA group compared to the placebo group. Secondary endpoints include the effect of LOVAZA on other lipid targets (total cholesterol, LDL cholesterol, HDL-cholesterol), markers of systemic inflammation, markers of bone turnover, markers of insulin resistance, HIV-disease control (CD4+ counts, HIV viral loads), measures of hepatotoxicity (ALT), platelet function, and patient reports of adverse events. Omega-3 fatty acids may be a useful adjunct in the treatment of hypertriglyceridemia in HIV-infected patients, but additional controlled studies are needed to assess its safety and efficacy using a purified, standardized preparation.
Criteria:		Inclusion Criteria: - Ability and willingness to give informed consent - Age ≥ 18 years - HIV-1 infection documented at any time prior to study entry - Fasting plasma triglyceride value between 200 and 1000 mg/dL on two occasions within 4 weeks - Subjects must be receiving a stable antiretroviral medication regimen for > 3 months without any anticipated changes during the study interval - Females must not be pregnant or lactating. Females of childbearing potential and males must use a reliable means of contraception - On stable lipid modification pharmacotherapy for at least 8 weeks prior to study entry Exclusion Criteria - Hemoglobin A1C > 8.5 % - Uncontrolled hypothyroidism (TSH > 4.5) - HIV viral load > 5,000 copies/ml (cpm), - Active liver disease and/or liver transaminases greater than 2.0 X upper limit of normal - Active kidney disease or serum creatinine > 2.5 mg/dL - Myocardial infarction, unstable ischemic heart disease, stroke, or coronary revascularization procedure - Uncontrolled hypertension within 4 weeks of study entry (SBP > 180 mmHg or DBP > 100 mmHg) - Use of systemic cancer chemotherapy within 8 weeks of study entry - Pregnancy or breastfeeding - Drug or alcohol dependence, or other conditions which may affect study compliance - History of coagulopathy or use of anticoagulants such as warfarin - Use of omega-3 fatty acid preparation in the 12 weeks prior to randomization - Significant changes in clinical status from the Screening Visit which would preclude the patient from being an appropriate candidate. - Any of the following laboratory parameters: hematocrit < 25%, absolute neutrophil count < 1.5 x 10^9/L, platelets < 100 x 10^9/L or hemoglobin < 8.0 gm/dL
NCT ID:		NCT00346697
Primary Contact:		Principal Investigator Todd T. Brown, MD Johns Hopkins University Todd T. Brown, MD Phone: 410-955-2130 Email: tbrown27@jhmi.edu
Backup Contact:		N/A
Location Contact:		Washington, District of Columbia 20007 United States Joseph Timpone, MD Phone: 202-687-6845 Email: timponej@gunet.georgetown.edu Site Status: Recruiting

Click here to see:

Clinical trials for AIDS in Washington, District of Columbia

Data Source:		ClinicalTrials.gov
Date Processed:		May 19, 2013
Modifications to this listing:		Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"

First Name:

Last Name:

Email Address:

Confirm Email:

Daytime Phone (eg. 555-555-5555):

City:

State:

Zip Code:

Best Time to Call:

Morning	Afternoon	Evening
Please contact me by email instead of calling.

Questions/Comments:

I have read and agree with the Privacy Policy

I have reviewed the eligibility criteria and believe I am eligible for this clinical trial

I would like to be notified about new clinical trials.

NEARBY STUDIES

Within 25 Miles

Crohn's Disease - Chevy Chase MD

Crohn's Disease - Annapolis MD

Healthy Volunteers (Ages 18-50) - Bethesda MD

Alcohol - Bethesda MD

Irritable Bowel Syndrome with Diarrhea (IBS-D) - Chevy Chase MD

G6PD Deficient Adults (Ages 18 to 62) - Silver Spring MD

Excessive Daytime Sleepiness with Narcolepsy - Chevy Chase MD

Restless Legs Syndrome (RLS) - Chevy Chase MD

Irritable Bowel Syndrome (with diarrhea) - Annapolis MD

Gout - Manassas VA

Anti-Depressant Induced Sexual Dysfunction - Washington DC

Anti-Depressant Induced Sexual Dysfunction - Gaithersburg MD

Asthma (Ages 18-65) - Wheaton MD

Brain Tumor (Glioblastoma) - Bethesda MD

Crohn’s Disease or Ulcerative Colitis - Bethesda MD

Within 50 Miles

Type 2 Diabetes - Baltimore MD

Healthy Volunteers (Ages 18-75) - Baltimore MD

Smoking - Baltimore MD

Multiple Sclerosis - Baltimore MD

Orthostatic Hypotension - Baltimore MD

Chronic Fatigue Syndrome - Baltimore MD

Irritable Bowel Syndrome with Diarrhea (IBS-D) - Towson MD

Arthritis - Frederick MD

Parkinson's Disease - Baltimore MD

Postherpetic Neuralgia (Post-Shingles Pain) - Towson MD

Excessive Daytime Sleepiness with Narcolepsy - Towson MD

Smoking - Baltimore MD

Osteoarthritis of the Knee - Towson MD

Multiple Sclerosis - Baltimore MD

Asthma (Ages 18-65) - White Marsh MD

Anti-Depressant Induced Sexual Dysfunction - Baltimore MD

Alzheimer's Disease - Towson MD

Methamphetamine Use - Baltimore MD

Healthy Volunteers (Ages 18-60) - Baltimore MD

Healthy Volunteers (Ages 18-65) - Baltimore MD

Healthy Volunteers (Ages 18-55) - Baltimore MD

Healthy Volunteers (Ages 18-60) - Baltimore MD

Healthy Volunteers (Ages 18-65) - Baltimore MD

Within 100 Miles

Emphysema/COPD (Chronic Obstructive Pulmonary Disease) - Richmond VA

Pediatric Depression - Richmond VA

Polycystic Ovary Syndrome - Richmond VA

Arthritis - Hagerstown MD

Restless Legs Syndrome (RLS) - Charlottesville VA

Irritable Bowel Syndrome (with diarrhea) - Richmond VA

Irritable Bowel Syndrome (with diarrhea) - Richmond VA

Anti-Depressant Induced Sexual Dysfunction - Charlottesville VA

COPD (Emphysema and Chronic Bronchitis) - Richmond VA

COPD (Emphysema and Chronic Bronchitis) - Richmond VA1

COPD (Emphysema and Chronic Bronchitis) - Richmond VA3

COPD (Emphysema and Chronic Bronchitis) - Richmond VA

TRIAL ALERTS

HEALTH NEWS

RSS FEEDS

ABOUT TRIALS

LINK TO US

View Clinical Trial (Medical Research Study)

NEARBY STUDIES